Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study

详细信息    查看全文

• 作者：Yinghao Su (1)
  Ying Zheng (2)
  Wei Zheng (1)
  Kai Gu (2)
  Zhi Chen (1)
  Guoliang Li (1)
  Qiuyin Cai (1)
  Wei Lu (2)
  Xiao Ou Shu (1)
  
• 刊名：BMC Cancer
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：11
• 期：1
• 全文大小：4375KB
• 参考文献：1. Di CS, Baselga J: Management of breast cancer with targeted agents: importance of heterogenicity. / Nat Rev Clin Oncol 2010, 7:139鈥?47. CrossRef
  2. van 't Veer LJ, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, / et al.: Gene expression profiling predicts clinical outcome of breast cancer. / Nature 2002, 415:530鈥?36. CrossRef
  3. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. / Proc Natl Acad Sci USA 2003, 100:10393鈥?0398. CrossRef
  4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, / et al.: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. / JAMA 2006, 295:2492鈥?502. CrossRef
  5. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. / J Clin Oncol 2008, 26:2373鈥?378. CrossRef
  6. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. / Cancer 2007, 110:876鈥?84. CrossRef
  7. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, / et al.: Epidemiology of basal-like breast cancer. / Breast Cancer Res Treat 2008, 109:123鈥?39. CrossRef
  8. Parise CA, Bauer KR, Brown MM, Caggiano V: Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999鈥?004. / Breast J 2009, 15:593鈥?02. CrossRef
  9. Telli ML, Kurian AW, Chang ET, Keegan TH, Ford JM, Gomez SL: Asian race and breast cancer subtypes: A study from the California Cancer Registry. / Breast Cancer Res Treat 2011, 127:471鈥?78. CrossRef
  10. Liu ZB, Liu GY, Yang WT, Di GH, Lu JS, Shen KW, Shen ZZ, Shao ZM, Wu J: Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. / Oncol Rep 2008, 20:987鈥?94.
  11. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM: Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. / Breast Cancer Res Treat 2009, 115:325鈥?33. CrossRef
  12. Lin Y, Yin W, Yan T, Zhou L, Di G, Wu J, Shen Z, Shao Z, Lu J: Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. / BMC Cancer 2009, 9:342. CrossRef
  13. Zhao J, Liu H, Wang M, Gu L, Guo X, Gu F, Fu L: Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. / J Surg Oncol 2009, 100:89鈥?4. CrossRef
  14. Xing P, Li J, Jin F: A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. / Med Oncol 2010, 27:926鈥?31. CrossRef
  15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, / et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. / Arch Pathol Lab Med 2007, 131:18鈥?3.
  16. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W: Soy food intake and breast cancer survival. / JAMA 2009, 302:2437鈥?443. CrossRef
  17. Su Y, Shrubsole MJ, Ness RM, Cai Q, Kataoka N, Washington K, Zheng W: Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. / Cancer Epidemiol Biomarkers Prev 2006, 15:1719鈥?726. CrossRef
  18. Tavassoli FA, Devilee P: / World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. London, IARC Press; 2003.
  19. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO: Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. / J Clin Oncol 2008, 26:3153鈥?158. CrossRef
  20. Diaz LK, Sahin A, Sneige N: Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. / Ann Diagn Pathol 2004, 8:23鈥?7. CrossRef
  21. Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R, Pritchard J, Pereira T, Geyer C, Wolmark N: Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. / Cancer 2005, 103:164鈥?73. CrossRef
  22. Zarcone M, Amodio R, Campisi I, Cusimano R, Dolcemascolo C, Miceli V, Traina A, Macaluso M: Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002鈥?004. / Ann N Y Acad Sci 2009, 1155:222鈥?26. CrossRef
  23. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, / et al.: Differences in risk factors for breast cancer molecular subtypes in a population-based study. / Cancer Epidemiol Biomarkers Prev 2007, 16:439鈥?43. CrossRef
  24. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U: Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. / J Clin Oncol 2001, 19:354鈥?63.
  25. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE: HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. / Mayo Clin Proc 2002, 77:148鈥?54. CrossRef
  26. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS: Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups. / JAMA 2007, 298:2869鈥?876. CrossRef
  27. Suter NM, Ray RM, Hu YW, Lin MG, Porter P, Gao DL, Zaucha RE, Iwasaki LM, Sabacan LP, Langlois MC, Thomas DB, Ostrander EA: BRCA1 and BRCA2 mutations in women from Shanghai China. / Cancer Epidemiol Biomarkers Prev 2004, 13:181鈥?89. CrossRef
  28. Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL: Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. / Cancer Epidemiol Biomarkers Prev 2009, 18:1807鈥?814. CrossRef
  29. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ: Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. / Breast Cancer Res 2009, 11:R31. CrossRef
  30. Ismail-Khan R, Bui MM: A review of triple-negative breast cancer. / Cancer Control 2010, 17:173鈥?76.
  31. Loi S, Sotiriou C, Buyse M, Rutgers E, Van't Veer L, Piccart M, Cardoso F: Molecular forecasting of breast cancer: time to move forward with clinical testing. / J Clin Oncol 2006, 24:721鈥?22. CrossRef
  32. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, / et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. / Proc Natl Acad Sci USA 2003, 100:8418鈥?423. CrossRef
  33. Bhargava R, Dabbs DJ: Luminal B breast tumors are not HER2 positive. / Breast Cancer Res 2008, 10:404. CrossRef
  34. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, / et al.: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. / J Natl Cancer Inst 2009, 101:736鈥?50. CrossRef
  35. Florescu A, Amir E, Bouganim N, Clemons M: Immune therapy for breast cancer in 2010-hype or hope? / Curr Oncol 2011, 18:e9-e18. CrossRef
  36. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. / J Clin Oncol 2010, 28:2784鈥?795. CrossRef
  37. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/292/prepub
  
• 作者单位：Yinghao Su (1)
  Ying Zheng (2)
  Wei Zheng (1)
  Kai Gu (2)
  Zhi Chen (1)
  Guoliang Li (1)
  Qiuyin Cai (1)
  Wei Lu (2)
  Xiao Ou Shu (1)
  
  1. Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2525 West End Ave, Suite 600, Nashville, TN, 37203-1738, USA
  2. Shanghai Institute of Preventive Medicine, 1380 Zhong Shan Road (W), Shanghai, 200336, China
  
• ISSN：1471-2407

文摘

Background Molecular classification of breast cancer is an important prognostic factor. The distribution of molecular subtypes of breast cancer and their prognostic value has not been well documented in Asians. Methods A total of 2,791 breast cancer patients recruited for a population-based cohort study were evaluated for molecular subtypes of breast cancer by immunohistochemical assays. Data on clinicopathological characteristics were confirmed by centralized pathology review. The average follow-up of the patients was 53.4 months. Overall and disease-free survival by molecular subtypes of breast cancer were evaluated. Results The prevalence of the luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), and triple-negative subtypes were 48.6%, 16.7%, 13.7%, and 12.9%, respectively. The luminal A subtype was more likely to be diagnosed in older women (P = 0.03) and had a stronger correlation with favorable clinicopathological factors (smaller tumor size, lower histologic grade, and earlier TNM stage) than the triple-negative or HER2 subtypes. Women with triple-negative breast cancer had a higher frequency of family history of breast cancer than women with other subtypes (P = 0.048). The 5-year overall/disease-free survival percentages for the luminal A, luminal B, HER2, and triple-negative subtypes were 92.9%/88.6%, 88.6%/85.1%, 83.2%/79.1%, and 80.7%/76.0%, respectively. A similar pattern was observed in multivariate analyses. Immunotherapy was associated with improved overall and disease-free survival for luminal A breast cancer, but reduced disease-free survival (HR = 2.21, 95% CI, 1.09-4.48) for the HER2 subtype of breast cancer. Conclusions The triple-negative and HER2 subtypes were associated with poorer outcomes compared with the luminal A subtype among these Chinese women. The HER2 subtype was more prevalent in this Chinese population compared with Western populations, suggesting the importance of standardized HER2 detection and anti-HER2 therapy to potentially benefit a high proportion of breast cancer patients in China.